![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser, or freeze dryer, that can be used for both Horizon’s commercial medicines, including its rare disease biologics TEPEZZA, KRYSTEXXA and UPLIZNA and development compounds.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: $65.0 million Upfront Cash: $65.0 million
Deal Type: Acquisition June 17, 2021